Biotest GmbH & Co KGaA (Biotest), a subsidiary of Grifols SA, develops, manufactures, and distributes biological medicines from human blood plasma or manufactured through biotechnology methods. Its medicines are used in the areas of clinical immunology, haematology, and intensive care medicine.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biotest focuses its research and development initiatives on plasma proteins, with significant efforts directed towards the development and approval of new products such as Fibrinogen and Trimodulin. Fibrinogen received approval in Germany and the US in December 2025, while Trimodulin is in rapid development for submission. The company is also enhancing existing products to increase patient benefits and achieve new indications and approvals. A notable development is the autoinjector for Zutectra, submitted to the European Medicines Agency for marketing authorization. Biotest collaborates with Grifols for global manufacturing and marketing of new products and has selected Kedrion Biopharma Inc. as the distribution partner for Yimmugo in the US. Biotest's R&D units focus on clinical immunology, intensive care medicine, and haematology. These units are responsible for managing the company's R&D activities, including the development of new products and further development of existing ones, particularly in the areas of plasma proteins and clotting factors. The product pipeline includes IgG Next Generation/Yimmugo (BT595) for Primary Immune Deficiency and Idiopathic Thrombocytopenic Purpura, Fibrinogen/Prufibry/Fesilty (BT524) for congenital and acquired fibrinogen deficiency, and Trimodulin (BT588) for severe community-acquired pneumonia. Biotest has a technology transfer and license agreement with Grifols, enabling the global manufacturing and marketing of new product developments. In FY2025, the company spent EUR66.7 million on R&D, which as a percentage of revenue, stood at 10.3% and grew 17.4% YoY.